Clinical review report: Netupitant/palonosetron 300 mg/0.5 mg (Akynzeo) (Purdue Pharma)
The objective of the review was to identify, summarize, and critically assess the beneficial and harmful effects of Netupitant/palonosetron (NEPA) in preventing chemotherapy-induced nausea and vomiting (CINV) for patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemot...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, June 2018
|
Edition: | Version: final |
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of the review was to identify, summarize, and critically assess the beneficial and harmful effects of Netupitant/palonosetron (NEPA) in preventing chemotherapy-induced nausea and vomiting (CINV) for patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC) |
---|---|
Physical Description: | 1 PDF file (96 pages) illustrations |